Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

VIP: A very important protein in arthritis

Many studies have shown that immune system modulation can be used to treat various forms of arthritis. A vasoactive intestinal peptide has recently been shown to have potent anti-inflammatory effects, indicating a new therapeutic approach for inflammatory arthritis (pages 563–568).

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Potential beneficial effects of VIP in arthritis.

Steve Horwitz

References

  1. Firestein, G.S. Etiology and pathogenesis of rheumatoid arthritis. in Textbook of Rheumatology, 6th edn. (eds. Kelley, W.N et al.) 921–966 (W.B. Saunders, Philadelphia, 2001).

    Google Scholar 

  2. Delgado, M., Abad, C., Martinex, C., Leceta, J. & Gomariz, R.P. Vasoactive intestinal protein prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nature Med. 7, 563–568 (2001)

    Article  CAS  Google Scholar 

  3. Firestein, G.S, Alvaro-Gracia, J.M. & Maki, R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J. Immunol. 144, 3347–3353 (1990).

    CAS  PubMed  Google Scholar 

  4. Chabaud, M. et al. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 42, 963–970 (1999).

    Article  CAS  Google Scholar 

  5. Miossec, P. & van den Berg, W. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum. 40, 2105–2015 (1997).

    Article  CAS  Google Scholar 

  6. Gomariz, R.P., Martinez, C., Abad, C., Leceta, J. & Delgado, M. Immunology of VIP: a review and therapeutical perspectives. Curr. Pharm. Des. 7, 89–111 (2001).

    Article  CAS  Google Scholar 

  7. Joosten, L. A. et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum. 40, 249–260 (1997).

    Article  CAS  Google Scholar 

  8. Boyle, D.L. et al. Intra-articular IL-4 gene therapy in arthritis: anti-inflammatory effect and enhanced Th2 activity. Gene Ther. 6, 1911–1918 (1999).

    Article  CAS  Google Scholar 

  9. Kong, Y.Y. et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304–309 (1999).

    Article  CAS  Google Scholar 

  10. Dechanet, J. et al. Interleukin-4 but not interleukin-10 inhibits the production of leukemia inhibitory factor by rheumatoid synovium and synoviocytes. Eur. J. Immunol. 24, 3222–3228 (1994).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Firestein, G. VIP: A very important protein in arthritis. Nat Med 7, 537–538 (2001). https://doi.org/10.1038/87859

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/87859

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing